drugset / Trial / NCT01602289
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of LY2875358 in Japanese participants with cancer that is advanced and/or may have spread to another part of the body.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emibetuzumab | Monoclonal antibody | 700 mg | Intravenous |
| Subject | Emibetuzumab | Monoclonal antibody | 2000 mg | Intravenous |
| Background | Erlotinib | Small molecule | 150 mg | Oral |
| Background | Gefitinib | Small molecule | 250 mg | Oral |